Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza.
Novo Nordisk has its sights set on Mexico. The Danish drugmaker has put that country next on its list to debut liraglutide in its new guise as a weight-loss drug.
France's Innate Pharma has signed a deal to pay Novo Nordisk $2.7 million up front and as much as $27 million in milestones for exclusive rights to the pair's Phase II-ready cancer immunotherapy.
Given the thousands of pharma sales layoffs over the past several years--and recruiting focused on emerging markets, especially China--staffing up in the U.S. or Europe is out of the ordinary. Yet t hat's just what Novo Nordisk has been doing: hiring reps by the hundred in the U.S.
Zosano Pharma, the developer of a microneedle patch for various applications, has signed on with pharma giant Novo Nordisk to deliver semaglutide, an analogue used to treat Type 2 diabetes. Zosano is set to collect $60 million for the first product in the deal and $55 million for each additional one.
Novo Nordisk, the world leader in the production of insulin drugs, today reported growth across the board for 2013. But the perennially cautious drugmaker did not raise sales guidance for this year as much as investors were expecting.
Trialbee informs people about upcoming trials by talking directly to patient groups on social media and through mobile apps.
First, South Africa proposed patent-law changes that would help foster generic drugs. Then, Big Pharma and its smaller colleagues in the country's pharma association hatched a counter-offensive: a $600,000 lobbying campaign against the measure. Now, Novo Nordisk has quit that group, the Innovative Pharmaceutical Association of South Africa (Ipasa), in protest.
Strategic reviews, sales and spinoffs are trendy in Big Pharma these days. Now, the Danish drugmaker Novo Nordisk has joined the bunch. Novo says it's weighing an initial public offering for its IT subsidiary, NNIT, and has hired a new CFO for the unit to handle the review.
The Federal Trade Commission may now have the right to challenge pay-for-delay deals, but drugmakers can still stall the launches of competing generic products. And that's exactly what a group of healthcare purchasing companies is accusing Novo Nordisk of doing to copies of its diabetes drug Prandin.